Hepatocyte growth factor (HGF) is a mitogen for hepatocytes, but it is not clear whether HGF stimulates or inhibits hepatocarcinogenesis. We previously reported that HGF transgenic mice under the metallothionein gene promoter developed benign and malignant liver tumors spontaneously after 17 months of age. To elucidate the role of HGF in hepatocarcinogenesis, diethylnitrosamine (DEN) was administered to HGF transgenic mice. HGF overexpression accelerated DENinduced hepatocarcinogenesis, often accompanied by abnormal blood vessel formation. In this study, 59% of transgenic males (versus 20% of wild-type males) and 39% of transgenic females (versus 2% of wild-type females) developed either benign or malignant liver tumors by 48 weeks (P50.005, P50.001, respectively). Moreover, 33% of males and 23% of female transgenic mice developed hepatocellular carcinoma (HCC), while none of the wild-type mice developed HCC (P50.001, P50.005, respectively). Enhanced kinase activity of the HGF receptor, Met, was detected in most of these tumors. Expression of vascular endothelial growth factor (VEGF) was up-regulated in parallel with HGF transgene expression. Taken together, our results suggest that HGF promotes hepatocarcinogenesis through the autocrine activation of the HGF-Met signaling pathway in association with stimulation of angiogenesis by HGF itself and/or indirectly through VEGF.
Introduction
Hepatocyte growth factor (HGF) is a polypeptide originally characterized as a highly potent hepatocyte mitogen (Gohda et al., 1988; Nakamura et al., 1989) . More recent studies have revealed that HGF is a multifunctional cytokine and can elicit mitogenic, motogenic, and morphogenic responses in a variety of cultured epithelial cells expressing the transmembrane tyrosine kinase receptor, Met (Brinkmann et al., 1995; Zarnegar and Michalopoulos, 1995) . HGF is expressed in a multitude of mesenchymally-derived cells and Met expression has been detected in the epithelium of most tissues, indicating that HGF-Met signal transduction pathway helps mediate mesenchymal-epithelial interactions Montesano et al., 1991; Rosen et al., 1994) .
c-met was ®rst cloned as a proto-oncogene through its ability to transform NIH3T3 cells (Park et al., 1986) and identi®ed as a HGF receptor . Robust expression of the c-met proto-oncogene has been documented in diverse human and mouse tumors including hepatocellular carcinomas (HCCs) (Prat et al., 1991; Rong et al., 1992 Rong et al., , 1993 D'Errico et al., 1996) , and the c-met gene is ampli®ed in some carcinomas of the gastrointestinal tract (Di Renzo et al., 1995; Kuniyasu et al., 1992) . Moreover, activating mutations within the tyrosine kinase domain of c-met have been reported in human renal papillary carcinomas and childhood HCCs (Schmidt et al., 1997; Park et al., 1999) . In addition, coexpression of HGF-Met has been identi®ed in a variety of transformed cultured cells and in some tumors (Bellusci et al., 1994; Tuck et al., 1996; Rahimi et al., 1996) . Taken together, these studies suggest that activation of HGF-Met signaling can be intimately associated with neoplastic transformation.
Paradoxically, however, HGF has also been reported to inhibit the growth of certain carcinoma cells. With respect to HCC, HGF was ®rst reported to show antiproliferative eects on some HCC cell lines, whereas it had a mitogenic eect on others (Tajima et al., 1991; Shiota et al., 1992; Miyazaki et al., 1992) . Furthermore, both stimulatory and inhibitory eects of exogenous administration of HGF on carcinogentreated rats have been reported (Liu et al., 1995; Yaono et al., 1995; Ogasawara et al., 1998) . There are also con¯icting reports in HGF transgenic mice. We previously reported that transgenic mice harboring a full-length mouse HGF cDNA under the control of the mouse metallothionein (MT) gene promoter induced liver tumors, which arose spontaneously in six independent transgenic lines after 17 months (Sakata et al., 1996) . In contrast, overexpression of a human HGF cDNA under the regulation of the albumin promoter in transgenic mice did not induce HCC (Shiota et al., 1994) . Moreover, the HGF transgene appeared to inhibit hepatocarcinogenesis in bitransgenic mice overexpressing c-myc (Santoni-Rugiu et al., 1996) or transforming growth factor alpha (TGF-a) (Shiota et al., 1995) . Therefore, whether HGF participates in hepatocarcinogenesis remains to be resolved.
Here we report the promoting eect of HGF on diethylnitrosamine (DEN)-induced hepatocarcinogenesis in MT-HGF transgenic mice, and provide characterization of these liver tumors at histopathological and molecular levels.
Results

Chemical induction of liver tumors in HGF transgenic mice
A signi®cant dierence in the development of liver tumors was observed at 48 weeks of age between HGF transgenic mice and wild-type mice treated with DEN (Table 1) . In males, 59% (16/27) of HGF transgenic mice developed grossly visible liver tumors, although only 20% (6/30) of wild-type mice had such tumors (P50.005).
Interestingly, this promoting eect of HGF on liver tumorigenesis was also detected in females, although females are known to be resistant to HCC in experimental mouse models, including those employing chemical carcinogenesis (Farber and Sarma, 1987; Pressumann, 1988; Takagi et al., 1993) . Unfortunately, it was dicult to monitor HGF transgenic females over long periods because more than half of females died as a result of renal failure or intestinal disease, as described previously (Takayama et al., 1997a (Takayama et al., , 2001 . Nonetheless, 39% (12/31) of HGF transgenic females developed liver tumors by 40 weeks. In contrast, only 2% (1/42) of wild-type females developed liver tumors by 48 weeks (P50.001). Liver tumors in HGF transgenic mice were larger in size and more numerous compared to those arising in wild-type mice. This dierence was extremely evident at 48 weeks male mice. 100% (4/4) of HGF transgenic mice had a number of (6+1.8 per mouse) frank liver tumors which are more than 5 mm in diameter, whereas none (0/5) of wild-type developed such tumors (P50.001).
With respect to progression to malignancy, 33% (9/ 27) and 23% (7/31) of male and female HGF transgenic mice developed HCCs, respectively (Table  2 ). In contrast, no HCC was found in male or female wild-type mice (P50.001, P50.005, respectively). Several studies reported that cells expressing both HGF and c-met show enhanced metastasis in vivo (Bellusci et al., 1994; Rong et al., 1994; Jeers et al., 1996) , but in the present study, only one HCC showed multiple metastasis to the lung by 48 weeks. Prolonged observation might be necessary for the study of metastasis in this model. Liver growth over the course of this study was determined by measuring liver weight relative to total body weight. Table 3 shows that transgenic mouse liver weight was much greater than that of wild-type mice at each time point. The liver weight in 40-week-old HGF transgenic females with multiple tumors was about threefold greater than agematched wild-type.
Histopathological and immunohistochemical analyses
Histopathological analysis of livers of treated and untreated HGF transgenic mice showed striking heterogeneity in hepatocytes and numerous small hepatocytes surrounding portal veins (Sakata et al., 1996) . Livers from DEN-treated transgenic mice contained more preneoplastic foci per unit area than wild-type at 16 weeks, although foci could not be evaluated at later time points because of coalescing tumors (Table 4 ). This preneoplastic change was also noted in transgenic females, similar to transgenic males. Notably, neither in¯ammation nor ®brosis was found in livers of transgenic and wild-type mice in this study, in sharp contrast to human. HCCs developing in HGF transgenic mice were composed of trabecular ( Figure 1A ), solid, and/or pseudoglandular type (data not shown), while none of the wild-type mice developed HCCs ( Figure 1B ). Macroscopic and microscopic aberrant neovascularization were often observed in transgenic tumors ( Figure 1C ), compared to wild-type tumors ( Figure 1D ). Some of HCCs in transgenic mice were accompanied peliosis-like change ( Figure 1E ), which is occasionally observed in human liver due to unknown cause (Craig et al., 1989) . To further quantify this overt increase in blood vessels, immunohistological analysis of endothelial cells was carried out using von -Willebrand Factor (vWF) antibodies ( Figure 1F ). The area of blood vessels in liver tumors of DEN-treated transgenic mice was signi®cantly larger than in those of wild-type mice ( Figure 2 ).
Analysis of transcripts of HGF and its receptor (c-met) in livers of carcinogen-treated transgenic mice
Our preliminary data showed that HGF transgene expression was not elevated by DEN administration (data not shown). To determine if hepatocarcinogenesis in HGF transgenic mice consistently correlated with further enhancement in HGF transgene expression, HGF expression was analysed in transgenic tumors and adjacent nontumorous tissues. Northern blot analyses showed that ®ve of six (83%) tumors exhibited HGF transgene transcript levels that were higher than those found in adjacent, grossly normal, transgenic tissue ( Figure 3 ). Endogenous c-met transcript levels were detected but no apparent dierences were noted between tumors and adjacent liver tissues ( Figure 3 ). c-met gene ampli®cation was not found in these tumors (data not shown).
Analysis of Met protein levels and activity
To quantify levels and phosphorylation of Met protein, extracts of liver tumors were subjected to immunoprecipitation using an anti-Met antibody, followed by Western blot analysis using either an anti-Met antibody or an anti-phosphotyrosine antibody. Figure 4 shows that levels of Met protein were in general agreement with the c-met transcript data. Met tyrosine phosphorylation was then determined in extracts obtained from transgenic tumors and adjacent nontumorous tissue. Met tyrosine phosphorylation was enhanced in three of four (75%) tumors, which showed elevated HGF transgene expression relative to adjacent tissue (Figure 4 ), suggesting that activation of Met can promote liver tumorigenesis.
Analysis of expression of VEGF in carcinogen-treated or -untreated transgenic mice
Because several reports have documented that HGF can induce VEGF expression in vitro (Van Belle et al., 1998; Moriyama et al., 1998; Gille et al., 1998) and because liver tumors in HGF transgenic mice showed abnormal blood vessel formation, we analysed VEGF expression in tumor and adjacent tissue from transgenic and wild-type livers. A 4.2 kb transcript was observed in both mice, and an additional 3.7 kb transcript was observed uniquely in HGF transgenic mice livers (Figure 4) . Northern blot analysis showed that ®ve of six (83%) tumors arising in DEN-treated HGF transgenic mice possessed 3.7 kb VEGF expression levels that were higher than those found in adjacent, non-tumorous, transgenic tissue. Moreover, 3.7 kb VEGF transcript was elevated in parallel with HGF transgene expression, suggesting that 3.7 kb VEGF overexpression is upregulated by HGF overexpression in these tumors (Figure 4) .
Discussion
In the present study, we demonstrated in vivo that HGF overexpression promotes hepatocarcinogenesis in transgenic mice when initiated with DEN, a wellcharacterized genetic mutagen, despite the ability of HGF to inhibit the growth of some HCC cell lines in vitro (Tajima et al., 1991; Shiota et al., 1992) . We also demonstrated that liver tumorigenesis in HGF transgenic mice is driven by the creation of HGF-Met autocrine loops, as evidenced by elevation of both HGF expression and c-Met phosphorylation in tumors relative to adjacent tissues. Moreover, our data indicated that this promotion may be mediated through enhanced angiogenesis provided by HGF itself, and/or indirectly through the induction of VEGF. The acquisition of autonomous growth has been strongly implicated in the development and progression of HCCs (Farber and Sarma, 1987) . Several growth factor signals, including TGF-a-epidermal growth factor receptor (EGFR), HGF-Met, and VEGF-VEGF receptor, are reported to participate in this autonomous growth (Yeh et al., 1987; Suzuki et al., 1996) . However, the role of HGF-Met signaling in hepatocarcinogenesis has not been clearly established because of somewhat con¯icting reports in the literature (Tajima et al., 1991; Shiota et al., 1992; Miyazaki et al., 1992; Liu et al., 1995; Yaono et al., 1995; Ogasawara et al., 1998) . The involvement of HGF-Met autocrine loops in tumorigenesis in other cell types has been clearly established both in vitro and in vivo (Bellusci et al., 1994; Tuck et al., 1996) . A multitude of human cell lines and tumors, particularly sarcomas, overexpress both Met and its ligand (Rong et al., 1993; Tuck et al., 1996) . In fact, diverse tumors developed in our HGF transgenic mice, including melanoma and rhabdomyosarcoma, demonstrating the formation of HGF-Met autocrine loops through forced expression of the transgene and overexpression of endogenous receptor (Takayama et al., 1997b) . In liver tumors in this model, Met kinase activity was enhanced in tumorous tissue, but not in adjacent tissue, in accordance with HGF transgene expression. These results suggest that hepatocarcinogenesis requires the selection of cells capable of expressing the HGF transgene in a strong, constitutive fashion, providing a mechanism for autonomous cellular proliferation through autocrine signal transduction. This is reminiscent of the behavior of NIH3T3 and C127 cells cotransfected with constructs expressing both HGF and Met, which demonstrated a greatly strengthened transformed phenotype (Rong et al., 1994; Jeers et al., 1996) .
These ®ndings on the consequences of HGF-Met autocrine signaling in the liver are similar to those associated with perturbation of signaling by other receptor tyrosine kinases. A number of studies have shown that TGF-a-EGFR signaling is involved in liver tumorigenesis (Yeh et al., 1987; Hsia et al., 1991) . In fact, robust overexpression of human TGF-a in transgenic mouse (line MT42) induced liver tumor development (Jhappan et al., 1990; Takagi et al., 1992) . Strong expression of TGF-a in transgenic mouse hepatocytes activates in autocrine growth stimulatory loop that permits autonomous replication in culture (Wu et al., 1994a,b) . Interestingly, these liver tumors also showed elevated TGF-a transgene transcript levels relative to adjacent tissue (Jhappan et al., 1990) . It is intriguing to speculate that the similar tumor promoting eect observed in the two distinct autocrine-loops, HGF-Met and TGF-a-EGFR, might represent the activation of pathways shared by a variety of receptor tyrosine kinase family members.
The dramatic acceleration of liver tumorigenesis by DEN in transgenic mice, from over 17 months in untreated mice (Sakata et al., 1996) to as early as 6 months in treated mice, suggests that HGF acts as a promoter of DEN-initiated hepatocytes. One mechanism by which chronically overexpressed HGF may collaborate with DEN is through dysregulation of cell growth, as documented previously in transgenic hepatocytes (Sakata et al., 1996) , which could facilitate the ®xation of promutagenic lesions induced by DEN. In another mechanism, the anti-apoptotic eects of HGF on hepatocytes may facilitate hepatocarcinogenesis, as it was previously documented that HGF blocked massive Fas-mediated liver apoptosis (Kosai et al., 1998) . HGF-Met signaling may encourage the survival of initiated cells that would otherwise succumb to mutation-induced death. In fact, our male and female HGF transgenic mice showed more preneoplastic foci at 16 weeks than FVB. This might explain the high incidence of tumors in transgenic female mice in the absence of hormonal manipulation.
Angiogenesis is implicated in cancer development, progression, growth, and metastasis (Fidler and Ellis, 1994; Folkman, 1995) . Among various angiogenic factors, VEGF is one of the most important factors in hepatocarcinogenesis (Mise et al., 1996; Suzuki et al., 1996) . Five dierent molecular species resulting from alternative splicing of the VEGF gene have been identi®ed according to their number of amino acids; VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206 (Houck et al., 1991; Tischer et al., 1991) . All isoforms dier in eciency of secretion but act similarly by stimulating mitogenesis and migration of vascular endothelial cells, and all increase vascular permeability (Houck et al., 1991) . Recent studies have shown that administration of HGF induces upregulation of VEGF in various cell types (Van Belle et al., 1998; Moriyama et al., 1998; Gille et al., 1998) . Although Van Belle et al. (1998) reported that administration of recombinant human HGF induced three principal isoforms (VEGF 121, VEGF 165, VEGF 189) in smooth muscle cells, we found that HGF overexpression in the liver uniquely upregulated 3.7 kb transcripts, corresponding to VEGF164 (VEGF165 in human). We demonstrated here that VEGF transcription was upregulated in parallel with HGF transgene expression. It is noteworthy that both macroscopic and microscopic examinations revealed abnormal blood vessel formation and intrahepatic hemorrhage in some HCCs. These results suggest that HGF can directly stimulate tumor progression through enhancement of angiogenesis (Matsumoto and Nakamura, 1996; Rosen et al., 1997) , and/or indirectly through induction of VEGF.
There are con¯icting reports on liver tumorigenesis in HGF transgenic mouse models. Overexpression of a human HGF cDNA under the regulation of the albumin promoter in transgenic mice, on the FVB strain, did not induce HCC (Shiota et al., 1994) . The level of expression achieved through the use of either the albumin or MT promoter may explain dierences in the consequence of the presence of the HGF transgene in the liver. The MT promoter with adjacent locus control regions induced a 2 ± 5-fold higher levels of serum HGF compared to that achieved by the albumin promoter (Sakata et al., 1996) . In addition, the mouse HGF cDNA used in our transgenic mice, instead of the human HGF cDNA, which demonstrates about 10% diversity in terms of amino acid conservation (Liu et al., 1993) , might be required to promote optimal activity of mouse Met. Transgenic mice overexpressing isoforms of HGF with ®ve deleted amino acids (d-HGF) under the regulation of albumin promoter has been documented (Bell et al., 1999) . Although d-HGF is reported to be functionally more potent than the full-length HGF, d-HGF transgenic mice showed no obvious dierence in liver/body weight ratio compared to control mice. However, d-HGF transgenic male mice, generated on a B6D2 (C57B66DBA2) strain, were three times more likely to develop HCC beyond 17 months (Bell et al., 1999) . Interestingly, the tumor promoting eects of d-HGF became more apparent in both male and female mice when initiated DEN (Bell et al., 1999) , consistent with our data described here.
HGF has been considered for the treatment of patients with liver cirrhosis (Ueki et al., 1999) , fulminant hepatic failure (Kosai et al., 1998) and liver transplantation (Ishiki et al., 1992; Fujiwara et al., 1993) as well as arteriosclerosis (Morishita et al., 2000) . However, we have previously shown that aberrant HGF expression induces developmental anomalies , renal dysfunction (Takayama et al., 1997a) and intestinal disease (Takayama et al., 2001) in mice, as well as spontaneous neoplastic transformation in older animals (Takayama et al., 1997b; Otsuka et al., 1998) . Here we present data demonstrating that environmental carcinogens can cooperate with, and dramatically accelerate, HGFmediated tumorigenesis in the liver, further supporting the oncogenic risk associated with persistent in vivo exposure to robust levels of HGF.
Materials and methods
Animals
MT-HGF line MH19 transgenic mice were generated on an albino FVB genetic background as described previously . Transgenic and control mice used in this study were typically produced from the mating of HGF heterozygote transgenic males with FVB females. Drinking water containing zinc was not used in this study. All mouse work was performed in accordance with the guidelines for animal care and use established by Gunma University School of Medicine.
Carcinogen-induced HCC
Diethylnitrosamine (DEN) (Sigma Chemical Co., St. Louis, MO, USA) was injected intraperitoneally in 15-day-old mice at a dose of 5 mg/g of body weight. At 21 days of age, mice were separated by sex and their genotype was determined. Study duration was 48 weeks, with interim sacri®ces at 16, 24, 32 and 40 weeks. Mice found moribund or dead were also examined for tumor development. Tissues were ®xed in either 10% buered formalin or 4% paraformaldehyde, embedded in paran, sectioned at 4 mm and stained with hematoxylin and eosin (H&E) for histopathological analysis. A portion of each tissue or tumor was snap frozen in liquid nitrogen and stored at 7808C for molecular analysis. For image analysis of hepatocellular foci, four representative sections per mouse were obtained from all liver lobes and the number and areaperimeter of each lesion were determined as described previously (Takagi et al., 1993) .
Analysis of RNA transcripts
HGF, c-met, and VEGF transcripts were detected by Northern blot hybridization. The mouse HGF cDNA probe and mouse c-met cDNA probe were synthesized by PCR as described previously . The human VEGF cDNA probe was synthesized by PCR using clone LA737 (kindly provided by Dr William J LaRochelle) as a template and the following set of primers: 5'-GTAAAAC-GACGGCCAGT-3' and 5'-CAGGAAACAGCTATGAC-3'. Total RNA was isolated using Isogen (Wako Pure Chemical Industries, Osaka, Japan) and 20 mg were loaded per lane onto 1% agarose/formaldehyde gels and transferred to nylon membranes after electrophoresis.
Analysis of Met and Met activation
Quanti®cation of Met and Met tyrosine phosphorylation was performed as described previously (Otsuka et al., 1998) . For immunoprecipitation, 500 mg of lysate were incubated with anti-Met antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h on ice. After the addition of Gamma-Bind G Sepharose (Boehringer Mannheim, Mannheim, Germany) and washing in RIPA buer, the immunoprecipitates were fractionated on 10% polyacrylamide gels (Biocraft). After electrophoretic transfer to nitrocellulose membranes (Bio-Rad Laboratories, Richmond, CA, USA), ®lters were blocked and then incubated with anti-Met antibody or anti-phosphotyrosine antibody (Upstate Biotechnology) overnight. Met was visualized by incubation with anti-goat antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology) by using enhanced chemiluminescence (Santa Cruz Biotechnology). Phosphotyrosine was visualized as above except that an anti-mouse antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology) was used.
Immunohistochemistry and quantification of blood vessel formation
For immunohistochemical analysis of von-Willebrand Factor (vWF), formalin-®xed and paran-embedded tissues were sectioned at a thickness of 4 mm. An anti-human vWF rabbit antibody (Dako Corporation, Carpinteria, CA, USA) was used at 1 : 200 concentration and antibody localization was visualized using Vectastain elite avidin-biotin-peroxidase complex kits (Vector Laboratories, Burlingame, CA, USA) according to the instructions provided by the manufacturer. Staining with vWF antibody, speci®c for endothelial cells, denoted blood vessel formation in liver tumor. The vascularized area was expressed as the percentage of blood vessels to the total area using National Institute of Health Image software. Sixteen randomly selected ®elds from eight tumors were analysed in each group.
Data analysis
All data were expressed as mean+s.e.m. Dierences in tumor incidence were examined for statistical signi®cance using the w 2 -test and those in preneoplastic lesion and blood vessel formation by one-way ANOVA followed by Fisher-PLSD analysis. A P value less than 0.05 denoted the presence of a statistically signi®cant dierence.
Abbreviations HGF, hepatocyte growth factor; DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; VEGF, vascular endothelial growth factor; MT, metallothionein; d-HGF, 5 amino acid deleted isoform of HGF; vWF, von-Willebrand Factor; TGF-a, transforming growth factor alpha; EGFR, epidermal growth factor receptor; H&E, hematoxylin and eosin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
